PDGFRB and breast carcinoma: Moreover, PDGFR-β is considered as a key regulatory molecule for tumor drug resistance for high expression of stromal PDGFR-β in breast cancer is associated with reduced benefit of tamoxifen (Paulsson et al., 2017).